|
Abbott Laboratories (ABT) |
|
|
|
ABT's Operating Income Growth by Quarter and Year
Abbott Laboratories's Operating Income results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
Operating Income Growth Y/Y▼
|
Operating Income Growth Y/Y▼
|
ABT Operating Income (in millions $) |
FY 2022 |
FY 2021 |
FY 2020 |
FY 2019 |
IV Quarter |
December |
-
|
2,378.00
|
2,432.00
|
1,389.00
|
III Quarter |
September |
-
|
2,546.00
|
1,495.00
|
1,198.00
|
II Quarter |
June |
-
|
1,392.00
|
672.00
|
1,206.00
|
I Quarter |
March |
2,912.00
|
2,109.00
|
758.00
|
739.00
|
FY |
|
2,912.00
|
8,425.00
|
5,357.00
|
4,532.00
|
ABT Operating Income first quarter 2022 Y/Y Growth Comment |
Abbott Laboratories achieved in the first quarter 2022, above Company average Operating Income growth of 38.07% year on year, to $ 2,912.00 millions.
Looking into first quarter 2022 results within Major Pharmaceutical Preparations industry 2 other companies have achieved higher Operating Income growth. While Abbott Laboratories' s Operating Income rise of 38.07% ranks overall at the positon no. 180 in the first quarter 2022.
Explain Operating Income growth
|
ABT Operating Income ( Y/Y Growth %) |
2022
|
2021 |
2020 |
2019 |
IV Quarter |
December |
- |
-2.22 % |
75.09 % |
19.23 % |
III Quarter |
September |
- |
70.3 % |
24.79 % |
20.4 % |
II Quarter |
June |
- |
107.14 % |
-44.28 % |
36.73 % |
I Quarter |
March |
38.07 % |
178.23 % |
2.57 % |
21.55 % |
FY |
|
- |
57.27 % |
18.2 % |
24.16 % |
ABT Operating Income (Quarter on Quarter Growth %) |
2022
|
2021 |
2020 |
2019 |
IV Quarter |
December |
- |
-6.6 % |
62.68 % |
15.94 % |
III Quarter |
September |
- |
82.9 % |
122.47 % |
-0.66 % |
II Quarter |
June |
- |
-34 % |
-11.35 % |
63.19 % |
I Quarter |
March |
22.46 % |
-13.28 % |
-45.43 % |
-36.57 % |
FY (Year on Year) |
|
- |
57.27 % |
18.2 % |
24.16 % |
Operating Income Y/Y Growth Statistics |
High |
Average |
Low |
64.74 % |
1.56 % |
-54.93 % |
(Dec. 31. 2007) |
|
(Sep. 30, 2015) |
|
Operating Income Y/Y Growth Statistics |
High |
Average |
Low |
64.74 % |
1.56 % |
-54.93 % |
(Dec. 31. 2007) |
|
(Sep. 30, 2015) |
|
Operating Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022 |
Abbott Laboratories's Q/Q Operating Income Growth
Operating Income Q/Q Growth Statistics |
High |
Average |
Low |
313.29 % |
14.13 % |
-75.54 % |
(June 30. 2012) |
|
(March 31, 2012) |
ABT's I. Quarter Q/Q Operating Income Comment |
Abbott Laboratories achieved in the I. Quarter 2022 above company average sequential Operating Income jump of 22.46%, to $ 2,912.00 millions, from $2,378.00 millions in the forth quarter. Major Pharmaceutical Preparations company is going from strength to strength, with reporting above normal increase, but also accelerating rate.
Within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Operating Income quarter on quarter growth. While Abbott Laboratories's Operating Income growth quarter on quarter, overall rank is 564. |
|
|
Operating Income Q/Q Growth Statistics |
High |
Average |
Low |
313.29 % |
14.13 % |
-75.54 % |
(June 30. 2012) |
|
(March 31, 2012) |
ABT's I. Quarter Q/Q Operating Income Comment |
Abbott Laboratories achieved in the I. Quarter 2022 above company average sequential Operating Income jump of 22.46%, to $ 2,912.00 millions, from $2,378.00 millions in the forth quarter. ABT is undergoing a remarkable growth, not just claiming better then normal gain, and also accelerating rate.
Within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Operating Income quarter on quarter growth. While Abbott Laboratories's Operating Income growth quarter on quarter, overall rank is 564. |
|
Abbott Laboratories's 12 Months Operating Income Growth Year on Year
Operating Income TTM Growth |
12 Months Ending (Mar 31 2022) |
12 Months Ending (Dec 31 2021) |
12 Months Ending (Sep 30 2021) |
12 Months Ending (Jun 30 2021) |
12 Months Ending (Mar 31 2021) |
Cumulative Operating Income 12 Months Ending |
$ 9,228.00 |
$ 8,425.00 |
$ 8,479.00 |
$ 7,428.00 |
$ 6,708.00 |
Y / Y Operating Income Growth (TTM) |
37.57 % |
57.27 % |
96.55 % |
84.91 % |
47.4 % |
Year on Year Operating Income Growth Overall
Ranking |
# 254 |
# 230 |
# 517 |
# 509 |
# 225 |
Seqeuential Operating Income Change (TTM) |
9.53 % |
-0.64 % |
14.15 % |
10.73 % |
25.22 % |
Seq. Operating Income Growth (TTM) Overall
Ranking |
# 180 |
# 523 |
# 745 |
# 837 |
# 306 |
Cumulative Operating Income growth
Comment |
Assuming the Abbott Laboratories's fiscal year would have ended in Mar 31 2022, Abbott Laboratories would have reprted above average annual Operating Income rise of 37.57% year on year, of $ 9,228 millions. This marks a slow-down of the companys growth trends and from the 57.27% increase in Dec 31 2021.
Among companies within the Healthcare sector 12 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 230 to 254. |
Operating Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
64.74 % |
1.56 % |
-54.93 % |
|
|
|
|
|
Operating Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
157.45 % |
13.47 % |
-65.4 % |
|
|
|
Operating Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 3 |
Sector |
# 9 |
S&P 500 |
# 180 |
|
Cumulative Operating Income growth
Comment |
Assuming the Abbott Laboratories's fiscal year would have ended in Mar 31 2022, Abbott Laboratories would have reprted above average annual Operating Income rise of 37.57% year on year, of $ 9,228 millions. This marks a slow-down of the companys growth trends and from the 57.27% increase in Dec 31 2021.
Among companies within the Healthcare sector 12 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 230 to 254. |
Operating Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
64.74 % |
1.56 % |
-54.93 % |
|
|
|
Operating Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
157.45 % |
13.47 % |
-65.4 % |
|
|
|
Operating Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 3 |
Sector |
# 9 |
S&P 500 |
# 180 |
|